An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients

Nicla La Verde, Marina Garassino, Claudia Bareggi, Paola Sburlati, Karen Borgonovo, Mariastella Dimaiuta, Cristina Mantica, Silvia Perrone, Valter Torri, Gabriella Farina

Research output: Contribution to journalArticle

Abstract

Aims and background: The purpose of the study was to evaluate the outcome of metastatic colorectal cancer patients treated, as first line, with 5-fluorouracil bolus/leucovorin + oxaliplatin, in terms of response, progression-free and overall survival. Materials and methods: A retrospective cohort of consecutive metastatic colorectal cancer patients, treated from 2003 to 2006, was identified and analyzed. All patients, without a central venous device, were treated with oxaliplatin + 5-fluorouracil and leucovorin. Results: Twenty-five metastatic colorectal cancer patients were treated. No 3-4 grade toxicity was observed. Five of 23 patients achieved a partial response: one of them resulted in a complete response after radiofrequency and another one after surgery. Fifteen of 23 patients had stable disease (one underwent radical surgery after chemotherapy, obtaining a complete remission) and 3 had progressive disease. Median progression-free survival was 7.2 months, and median overall survival was 30 months. Conclusions: Based on this case-series study, the regimen seems to offer a good control of disease (86.9%) and can be considered as an alternative choice for patients who cannot receive continuous infusion.

Original languageEnglish
Pages (from-to)557-561
Number of pages5
JournalTumori
Volume93
Issue number6
Publication statusPublished - Nov 2007

Keywords

  • 5-fluorouracil bolus
  • Central venous devices
  • Metastatic colorectal cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients'. Together they form a unique fingerprint.

  • Cite this

    La Verde, N., Garassino, M., Bareggi, C., Sburlati, P., Borgonovo, K., Dimaiuta, M., Mantica, C., Perrone, S., Torri, V., & Farina, G. (2007). An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients. Tumori, 93(6), 557-561.